Baidu
map

CNS Drug:抗精神病药物增加静脉血栓栓塞风险的研究进展

2018-03-19 石岩 环球医学

静脉血栓栓塞(VTE)是一种多发性疾病,包括深静脉血栓形成和肺栓塞。 每1000名成年人中,VTE每年约影响1.0~1.8人次,可能导致血栓后综合征(PTS)或慢性血栓栓塞性肺动脉高压(CTPH)等并发症,并可能导致相当高的死亡率。2018年1月,发表在《CNS Drugs》的一篇由瑞典和挪威研究者撰写的综述详细阐述了抗精神病药物增加VTE风险的最新进展。

静脉血栓栓塞(VTE)是一种多发性疾病,包括深静脉血栓形成和肺栓塞。 每1000名成年人中,VTE每年约影响1.0~1.8人次,可能导致血栓后综合征(PTS)或慢性血栓栓塞性肺动脉高压(CTPH)等并发症,并可能导致相当高的死亡率。2018年1月,发表在《CNS Drugs》的一篇由瑞典和挪威研究者撰写的综述详细阐述了抗精神病药物增加VTE风险的最新进展。

本文总结了抗精神病药使用过程中VTE风险的现有证据。越来越多的观察性研究显示,抗精神病药物使用者的VTE风险增加。尽管某些抗精神病药的使用与VTE相关,但目前的数据尚不能最终确定一代与二代抗精神病药物之间或不同单个化合物之间在VTE发病率方面的差异,也不能确定哪种抗精神病药物的VTE风险最低。

这一药物不良反应的发病机制的相关生物学原理尚未确定,但已经提出诸如药物诱导镇静、肥胖、抗磷脂抗体水平上升、血小板聚集增强、高同型半胱氨酸血症以及高泌乳素血症等假设。

精神疾病背后的潜在风险因素或许至少能部分解释风险增加的问题。药师应该注意到潜在的严重甚至有时会致命的药物不良反应,并考虑中断或转换发生了VTE的患者的抗精神病治疗方案。尽管支持证据有限,但应该在VTE风险情况下考虑预防性抗栓治疗。

原始出处:

Jnsson, A.K., Schill, J., Olsson, H. et al. Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence. CNS Drugs (2018) 32: 47. https://doi.org/10.1007/s40263-018-0495-7.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1955353, encodeId=ca5b195535311, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 05 03:25:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697661, encodeId=0ef2169e66162, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed May 09 14:25:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770079, encodeId=9d2c1e7007993, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Mon Jun 25 13:25:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914242, encodeId=088e19142428b, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Dec 29 02:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862302, encodeId=fcfa18623028e, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Oct 04 11:25:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300304, encodeId=c9713003044c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Mar 27 22:40:33 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380960, encodeId=855e1380960db, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513087, encodeId=0296151308e4b, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297784, encodeId=e2a429e78484, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Mar 19 20:43:36 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297763, encodeId=196429e76340, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 19 17:30:49 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2019-03-05 xue8602
  2. [GetPortalCommentsPageByObjectIdResponse(id=1955353, encodeId=ca5b195535311, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 05 03:25:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697661, encodeId=0ef2169e66162, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed May 09 14:25:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770079, encodeId=9d2c1e7007993, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Mon Jun 25 13:25:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914242, encodeId=088e19142428b, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Dec 29 02:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862302, encodeId=fcfa18623028e, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Oct 04 11:25:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300304, encodeId=c9713003044c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Mar 27 22:40:33 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380960, encodeId=855e1380960db, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513087, encodeId=0296151308e4b, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297784, encodeId=e2a429e78484, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Mar 19 20:43:36 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297763, encodeId=196429e76340, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 19 17:30:49 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-05-09 fusion
  3. [GetPortalCommentsPageByObjectIdResponse(id=1955353, encodeId=ca5b195535311, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 05 03:25:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697661, encodeId=0ef2169e66162, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed May 09 14:25:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770079, encodeId=9d2c1e7007993, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Mon Jun 25 13:25:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914242, encodeId=088e19142428b, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Dec 29 02:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862302, encodeId=fcfa18623028e, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Oct 04 11:25:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300304, encodeId=c9713003044c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Mar 27 22:40:33 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380960, encodeId=855e1380960db, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513087, encodeId=0296151308e4b, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297784, encodeId=e2a429e78484, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Mar 19 20:43:36 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297763, encodeId=196429e76340, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 19 17:30:49 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1955353, encodeId=ca5b195535311, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 05 03:25:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697661, encodeId=0ef2169e66162, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed May 09 14:25:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770079, encodeId=9d2c1e7007993, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Mon Jun 25 13:25:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914242, encodeId=088e19142428b, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Dec 29 02:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862302, encodeId=fcfa18623028e, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Oct 04 11:25:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300304, encodeId=c9713003044c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Mar 27 22:40:33 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380960, encodeId=855e1380960db, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513087, encodeId=0296151308e4b, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297784, encodeId=e2a429e78484, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Mar 19 20:43:36 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297763, encodeId=196429e76340, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 19 17:30:49 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-12-29 lg.zhao
  5. [GetPortalCommentsPageByObjectIdResponse(id=1955353, encodeId=ca5b195535311, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 05 03:25:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697661, encodeId=0ef2169e66162, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed May 09 14:25:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770079, encodeId=9d2c1e7007993, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Mon Jun 25 13:25:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914242, encodeId=088e19142428b, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Dec 29 02:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862302, encodeId=fcfa18623028e, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Oct 04 11:25:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300304, encodeId=c9713003044c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Mar 27 22:40:33 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380960, encodeId=855e1380960db, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513087, encodeId=0296151308e4b, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297784, encodeId=e2a429e78484, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Mar 19 20:43:36 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297763, encodeId=196429e76340, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 19 17:30:49 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-10-04 wangbingxhy
  6. [GetPortalCommentsPageByObjectIdResponse(id=1955353, encodeId=ca5b195535311, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 05 03:25:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697661, encodeId=0ef2169e66162, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed May 09 14:25:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770079, encodeId=9d2c1e7007993, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Mon Jun 25 13:25:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914242, encodeId=088e19142428b, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Dec 29 02:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862302, encodeId=fcfa18623028e, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Oct 04 11:25:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300304, encodeId=c9713003044c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Mar 27 22:40:33 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380960, encodeId=855e1380960db, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513087, encodeId=0296151308e4b, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297784, encodeId=e2a429e78484, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Mar 19 20:43:36 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297763, encodeId=196429e76340, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 19 17:30:49 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-03-27 Ramsey

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1955353, encodeId=ca5b195535311, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 05 03:25:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697661, encodeId=0ef2169e66162, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed May 09 14:25:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770079, encodeId=9d2c1e7007993, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Mon Jun 25 13:25:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914242, encodeId=088e19142428b, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Dec 29 02:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862302, encodeId=fcfa18623028e, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Oct 04 11:25:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300304, encodeId=c9713003044c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Mar 27 22:40:33 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380960, encodeId=855e1380960db, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513087, encodeId=0296151308e4b, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297784, encodeId=e2a429e78484, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Mar 19 20:43:36 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297763, encodeId=196429e76340, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 19 17:30:49 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1955353, encodeId=ca5b195535311, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 05 03:25:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697661, encodeId=0ef2169e66162, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed May 09 14:25:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770079, encodeId=9d2c1e7007993, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Mon Jun 25 13:25:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914242, encodeId=088e19142428b, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Dec 29 02:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862302, encodeId=fcfa18623028e, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Oct 04 11:25:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300304, encodeId=c9713003044c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Mar 27 22:40:33 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380960, encodeId=855e1380960db, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513087, encodeId=0296151308e4b, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297784, encodeId=e2a429e78484, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Mar 19 20:43:36 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297763, encodeId=196429e76340, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 19 17:30:49 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1955353, encodeId=ca5b195535311, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 05 03:25:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697661, encodeId=0ef2169e66162, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed May 09 14:25:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770079, encodeId=9d2c1e7007993, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Mon Jun 25 13:25:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914242, encodeId=088e19142428b, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Dec 29 02:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862302, encodeId=fcfa18623028e, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Oct 04 11:25:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300304, encodeId=c9713003044c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Mar 27 22:40:33 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380960, encodeId=855e1380960db, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513087, encodeId=0296151308e4b, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297784, encodeId=e2a429e78484, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Mar 19 20:43:36 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297763, encodeId=196429e76340, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 19 17:30:49 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-03-19 changjiu

    学习一下谢谢

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1955353, encodeId=ca5b195535311, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 05 03:25:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697661, encodeId=0ef2169e66162, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed May 09 14:25:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770079, encodeId=9d2c1e7007993, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Mon Jun 25 13:25:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914242, encodeId=088e19142428b, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Dec 29 02:25:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862302, encodeId=fcfa18623028e, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Oct 04 11:25:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300304, encodeId=c9713003044c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI06MUzr7AI0nTlsgpDTRvVB51yAMdGfTKe8roX48ibEeqHD1dz3UibUa9SibU24UPLcEozJiaSB67WvQ/132, createdBy=fca0106828, createdName=Ramsey, createdTime=Tue Mar 27 22:40:33 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380960, encodeId=855e1380960db, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513087, encodeId=0296151308e4b, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Wed Mar 21 07:25:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297784, encodeId=e2a429e78484, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Mar 19 20:43:36 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297763, encodeId=196429e76340, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 19 17:30:49 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-03-19 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

相关资讯

nature:多巴胺D2受体结构揭晓,有助于研发更安全的精神病药物

本周《自然》在线发表的一篇论文Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone报告了与常用抗精神病药物利培酮结合的多巴胺D2受体(DRD2)的结构——该受体是用于治疗精神病的药物的主要靶点。因为靶向该受体的药物与其他相关受体会产生相互作用,所以常常引起严重、有害的副作

LANCET NEUROL:药物Pimavanserin可缓解痴呆症患者的精神病,没有副作用

已发现一种新的抗精神病药物可缓解全球数百万患有阿尔茨海默病的人的恐怖和令人不安的症状。

Lancet Psychiat::虚拟现实可减轻精神障碍患者的偏执焦虑

据法新社 2 月 9 日报道,一项发表于 2 月 9 日《柳叶刀•精神病学》(The Lancet Psychiatry)的研究显示,虚拟现实 (VR) 疗法与标准疗法相结合可以减少精神障碍患者的偏执和焦情绪。

**检:坚决防止和纠正“假精神病”“被精神病”

为规范检察机关强制医疗决定程序监督工作,维护公共安全,维护诉讼参与人的合法权利,保障强制医疗程序的正确实施,最高检日前印发《人民检察院强制医疗决定程序监督工作规定》(下称《规定》),坚决防止和纠正犯罪嫌疑人“假冒精神病人”逃脱法律制裁和普通人“被精神病”而错误强制医疗。为提高监督准确性,及时发现“假精神病”和“被精神病”,《规定》明确要求,人民检察院办理公安机关移送的强制医疗案件,可以会见涉案精神

Neurology:精神类共病与多发性硬化残疾程度进展相关

研究认为对于多发性硬化患者,精神系统共病率较高,是疾病残疾程度进展的标志

别吵了,“游戏成瘾”真要被纳入精神病了!

多组统计数据显示,我国网络游戏成瘾比例高于欧美。

Baidu
map
Baidu
map
Baidu
map